About ClinSearch
- What makes ClinSearch different
- History and Core Values
- Board of Directors
- Executive management
- Senior consultants
What makes ClinSearch different
ClinSearch is a European Health Research Organization which provides Consultancy and Operational services for Medical Device and Drug Development. We offer more than quality at each step of your project, more than a highly qualified team, more than customer satisfaction… ClinSearch is committed to offer cost-effective solutions for designing and managing clinical evaluations, real-life studies or any other healthcare assessment. This is why ClinSearch is known as a company committed to results and has earned a reputation for delivering practical, measurable and high added-value data.
Our mission…
At ClinSearch we work to ensure that our team of highly qualified specialists in health sciences delivers the best quality results and a high level of availability to meet and exceed the needs of our customers. With this in mind ClinSearch provides outstanding solutions that are not only adapted but complete. Our aim is to help you promote your innovation in Europe’s growing market.
We do this by:
- Building long-term customer partnerships with customers to develop new approaches in conducting Clinical Trials or Epidemiological Studies
- Sharing our ideas to support your development plan strategies
- Promoting cost-effective solutions in a wide range of health research services
- Providing decision-making answers
- Assigning resources recognised for their knowledge, innovative research techniques, insightful analysis and recommendations
- Ensure rapid mobilization of experts networks
Working Together Results In Satisfaction!
History and core values
ClinSearch was created in 1999 by Fabrice Ruiz and Jérôme Seymour as a global health research company. Right from the start, ClinSearch has demonstrated great commitment to results and a high level of availability to our customers. This commitment policy has allowed us to establish true partnerships with customers who call upon us…
Dispersing our expertise, at the risk of losing it completely, is contrary to the very essence of our company. That is why we maintain a human size, and are active uniquely in our field of expertise, which allows us to offer solutions that are not only well adapted, but complete.
Board of directors
- Pr P. Cacoub, MD
- Internal Medicine & Cardiovascular diseases
- Dr J.-M. Feryn, PharmD
- Bacteriology
- F. Ruiz, MSc
-
Biotechnology & University Degree in Onco-haematology
Chairman of the Board - Dr J. Seymour, PhD
- Immunology
Executive Management
- Master in Biotechnology,
- 14 years of experience in biomedical research and epidemiology,
- Vice-President of a Master’s Engineering School.
- PhD in Immunology,
- 18 years of experience in biomedical research and epidemiology,
- 6 years in Medical Device,
- Field work for an American Contract Research Organisation (OMNICARE) in order to create the French entity (5 years as Deputy General Manager).
Senior consultants
- Sandy Maumus-Robert, PharmD, PhD Scientific Director
- Sandy is a doctor of pharmacy and has a PhD in epidemiology and public health. She also has a postgraduate diploma in toxicology and a postgraduate diploma in computer science. Sandy has a ten-year experience in epidemiology and biology and is the co-author of fourteen papers in peer-reviewed scientific journals. She joined ClinSearch in 2007.
- Cécile Train, MSc Project Director
- Cécile has been working for ClinSearch since 2001. She has extensive experience working in clinical research gained through monitoring activities as well as regulatory submissions. Cécile's expertise in project management was honed during several years spent working for internal projects and a two-year outsourcing mission for one of the world leading pharmaceutical companies. Today, she leads the Project Management Department of ClinSearch.
- Elisabeth Bauchspiess, MA Regulatory affairs, Quality Systems Manager
- Of German origin, Elisabeth has a master’s degree in social economics. She studied social and business economics at the University of Applied Sciences Nordhausen, at the Corvinus University of Budapest and at the ESCE Business School, in Paris. She has been trained on international quality standards and auditing methodology. Elisabeth joined ClinSearch in 2008.
- Marina Varastet, PhD Head of Medical Writing and Scientific Advisor
- Marina has a PhD in neuroscience. She has five years of experience in basic research and sixteen in clinical research and epidemiology. She is the co-author of twenty-eight papers in peer-reviewed scientific journals. Marina joined ClinSearch in 1999.
- Lætitia Finzi, MD, PhD Senior Medical Advisor and Medical Writer
- Lætitia is a former visceral surgeon. She has a PhD and a seven-year experience in basic science research. She is the co-author of fifteen papers in peer-reviewed scientific journals. Lætitia joined ClinSearch in 2008.
News
Morning Read: Non-profit designing free Wi-Fi architecture for hospitals >> Read
Managing retinal vein occlusion >> Read
Let Me Die on the Prairie by Frances Jane Crosby Van Alstyne >> Read
Publication: Volume 16, number 4 (Stevenson). Study found that no conclusive results can be provided on the cost-effectiveness of four non-invasive tests for liver fibrosis [the Enhanced Liver Fibrosis Test, FibroTest and FibroMAX and transient elastography (FibroScan)] in patients suspected of having alcohol-related liver disease. >> Read
Top headlines from HIMSS2012 (Tuesday edition) >> Read
Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis >> Read
Publication: Volume 16, number 3 (Hockenhull). Report finds that whilst some interventions targeted at mental health populations to reduce violence are well supported by the evidence a scattergun approach in the research literature provides little firm evidence for the majority of interventions. Evidence shows small-to-moderate effects for cognitive behavioural therapy for psychological interventions, and larger effects for atypical antipsychotic drugs. >> Read
How the NHS measures up to other health systems >> Read
Publication: Volume 16, number 5 (Ara). Although orlistat, sibutramine and rimonabant are all effective at reducing weight and body mass index and, compared with placebo, are all cost-effective, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. >> Read
Peter John Fenton >> Read
Publication: Volume 16, number 6 (Reeves). The verteporfin photodynamic therapy cohort study found that treatment and follow-up were much less frequent in routine clinical practice than in research trials and the cost-effectiveness was similar to the highest previous estimate. >> Read
Frederick Valentine Flynn >> Read